

# Kanwal P S Raghav

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7808646/publications.pdf>

Version: 2024-02-01

65  
papers

2,937  
citations

236925

25  
h-index

182427

51  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5071  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	1.4	2
2	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.	4.1	7
3	HepatoScore <sup>®</sup> 4: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. <i>Hepatology</i> , 2021, 73, 2278-2292.	7.3	10
4	Malignant Mesothelioma of the Peritoneum in Women. <i>American Journal of Surgical Pathology</i> , 2021, 45, 45-58.	3.7	11
5	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.	1.4	0
6	Cancer of Unknown Primary Presenting as Bone <sup>®</sup> Predominant or Lymph Node <sup>®</sup> Only Disease: A Clinicopathologic Portrait. <i>Oncologist</i> , 2021, 26, e650-e657.	3.7	3
7	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	3.7	21
8	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
9	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup> -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	3.0	31
10	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.	7.0	25
11	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.	9.4	37
12	Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. <i>JAMA Network Open</i> , 2021, 4, e2119934.	5.9	11
13	Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. <i>Current Oncology</i> , 2021, 28, 671-677.	2.2	27
14	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.	2.5	3
15	How quality of life can inform management decisions in later-line metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 1-16.	0.3	0
16	Quality-of-life concerns in patients with metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 2-6.	0.3	0
17	How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 13-14.	0.3	0
18	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	2.3	2

#	ARTICLE	IF	CITATIONS
19	International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. <i>JCO Precision Oncology</i> , 2020, 4, 6-19.	3.0	29
20	Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. <i>Oncology</i> , 2020, 98, 836-846.	1.9	6
21	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020, 61, 103030.	6.1	67
22	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.	6.4	18
23	Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. <i>Oncologist</i> , 2020, 25, e1807-e1811.	3.7	7
24	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	2.9	59
25	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	2.3	3
26	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	2.8	9
27	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal/Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
28	Natural history and prognostic factors for localised small bowel adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000960.	4.5	20
29	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	6.4	32
30	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	7.1	348
31	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	7.0	54
32	Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. <i>BMC Cancer</i> , 2019, 19, 965.	2.6	12
33	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	7.1	335
34	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	4.1	212
35	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.6	37
36	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2033-2041.	7.0	224

#	ARTICLE	IF	CITATIONS
37	Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 402.	7.1	11
38	Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1135-1141.	4.9	45
39	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	4.1	11
40	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.	6.3	26
41	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.	7.7	18
42	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.	6.3	53
43	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	7.0	225
44	Clinical and prognostic significance of circulating levels of angiotensin-1 and angiotensin-2 in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 37721-37732.	1.8	16
45	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	2.8	23
46	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	2.3	34
47	Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach. <i>Annals of Surgical Oncology</i> , 2017, 24, 1134-1134.	1.5	6
48	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	7.0	50
49	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	4.1	40
50	Underreporting of Research Biopsies from Clinical Trials in Oncology. <i>Clinical Cancer Research</i> , 2017, 23, 6450-6457.	7.0	15
51	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	1.5	32
52	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017, 17, 331.	2.6	11
53	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	4.1	45
54	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017, 24, 187-193.	1.5	62

#	ARTICLE	IF	CITATIONS
55	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	2.5	25
56	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. Journal of Gastrointestinal Oncology, 2017, 8, 199-212.	1.4	26
57	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	2.5	65
58	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. Oncotarget, 2016, 7, 54627-54631.	1.8	53
59	Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Medicine, 2016, 5, 239-247.	2.8	33
60	Favorable Subsets Among Cancers of Unknown Primary. , 2016, , 151-172.		1
61	Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS ONE, 2016, 11, e0154985.	2.5	22
62	Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. Oncologist, 2015, 20, e3-4.	3.7	3
63	Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 21193-21207.	1.8	9
64	Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	28
65	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist, 2013, 18, 1270-1277.	3.7	41